摘要
嵌合抗原受体T细胞(CAR-T)疗法是肿瘤过继免疫治疗的新手段。CAR-T细胞疗法治疗B细胞急性淋巴细胞白血病(B-ALL)的完全缓解率高达90%。然而,目前CAR-T细胞疗法在血液肿瘤的治疗过程中尚存在脱靶效应、毒副作用、体内持续时间短与复发率高等问题。此外,在CAR-T细胞治疗实体瘤方面的安全性和有效性虽已得到证实,但疗效还有待提高。本文对近年来CAR-T细胞治疗的研究进展及该领域中亟需解决的问题作一分析与展望。
Chimeric antigen receptor T cells(CAR-T)therapy is a new method of tumor immunotherapy.The complete response rate of CAR-T cell therapy for B cell acute lymphoblastic leukemia(B-ALL)is as high as 90%.However,there are some problems of CAR-T cell therapy in the treatment of blood tumor,such as off-target activity,toxic side effect,short duration of the body and high recurrence rate.In addition,the safety and efficacy of CAR-T cells in the treatment of solid tumors have been confirmed,but the efficacy remains to be improved.In this paper,the research progression of CAR-T cell therapy in recent years and the urgent problems in this field are analyzed and prospected.
作者
郑晓
蒋敬庭
ZHENG Xiao;JIANG Jingting(Department of Tumor Biological Treatment,the Third Affiliated Hospital of Soochow University,Jiangsu Engineering Research Center for Tumor Immunotherapy,Changzhou 213003,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2018年第7期655-660,共6页
Chinese Clinical Oncology
基金
国家科技支撑计划(2015BAI12B12)
国家自然科学基金面上项目(31570877
31570908)
常州市应用基础研究项目(CJ20160021)
江苏省检验医学重点实验室开放基金(JSKLM-2014-003)
关键词
肿瘤
嵌合抗原受体T细胞
肿瘤免疫治疗
Tumor
Chimeric antigen receptor T cells(CAR-T)
Tumor immunotherapy
